Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Nektar Therapeutics    NKTR

NEKTAR THERAPEUTICS

(NKTR)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/16/2019 10/17/2019 10/18/2019 10/21/2019 10/22/2019 Date
17.54(c) 17.77(c) 17.27(c) 17.73(c) 17.2(c) Last
1 927 573 1 517 835 4 904 111 2 026 151 1 565 220 Volume
+1.42% +1.31% -2.81% +2.66% -2.99% Change
More quotes
Financials (USD)
Sales 2019 106 M
EBIT 2019 -505 M
Net income 2019 -503 M
Debt 2019 129 M
Yield 2019 -
Sales 2020 183 M
EBIT 2020 -475 M
Net income 2020 -504 M
Finance 2020 384 M
Yield 2020 -
P/E ratio 2019 -5,98x
P/E ratio 2020 -6,10x
EV / Sales2019 29,7x
EV / Sales2020 14,4x
Capitalization 3 015 M
More Financials
Company
Nektar Therapeutics specializes in the research and development of drugs for the treatment of cancer, autoimmune diseases and chronic pain. Net sales break down by source of income as follows: - revenues from licensing and collaboration agreements (91.9%); - product sales (4.6%); - royalties... 
Sector
Biotechnology & Medical Research
Calendar
11/08 | 07:00amPresentation
More about the company
Surperformance© ratings of Nektar Therapeutics
Trading Rating : Investor Rating :
More Ratings
Latest news on NEKTAR THERAPEUTICS
10/21NEKTAR THERAPEUTICS : Change in Directors or Principal Officers (form 8-K)
AQ
10/16FINAL DEADLINE APPROACHING : Kessler Topaz Meltzer & Check, LLP Announces Deadli..
BU
10/16NKTR CLASS ACTION DEADLINE IN 1 DAY : Bernstein Liebhard LLP Reminds Investors o..
BU
10/15DEADLINE ALERT : Bragar Eagel & Squire, P.C. Reminds Investors That a Class Acti..
BU
10/02NEKTAR THERAPEUTICS : Announces Five Abstracts Accepted for Presentation at the ..
PR
10/01NEKTAR THERAPEUTICS : Change in Directors or Principal Officers (form 8-K)
AQ
10/01NEKTAR THERAPEUTICS : Announces Key Executive Promotions
PR
09/26Las Vegas Sands Shares Climb 5% as Stock Heads to S&P 500
DJ
09/26Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Thera..
PR
09/26NEKTAR THERAPEUTICS : Clinical Data Presented from PIVOT-02 Study of Bempegaldes..
PR
09/23NEKTAR THERAPEUTICS : Announces Abstract Accepted for Presentation at the 5th CR..
PR
09/12NKTR CLASS ACTION ALERT : Bernstein Liebhard LLP Announces the Filing of a Secur..
PR
09/04KESSLER TOPAZ MELTZER & CHECK, LLP : Announces Investor Securities Fraud Class A..
BU
09/03KESSLER TOPAZ MELTZER & CHECK, LLP : Securities Fraud Class Action Filed Against..
PR
08/30NEKTAR THERAPEUTICS : Other Events (form 8-K/A)
AQ
More news
News in other languages on NEKTAR THERAPEUTICS
09/27EN DIRECT DES MARCHES : ArcelorMittal, Airbus, Carrefour, Altran, Inventiva, ..
09/27STOCK MARKET PARIS : Donald Trump à quitte ou double
08/01WallStreet : Donald Trump plombe le S&P, les taux, le pétrole
More news
Analyst Recommendations on NEKTAR THERAPEUTICS
More recommendations
Sector news : Biotechnology & Medical Research - NEC
10/18GRAPHIC - TAKE FIVE : Super Saturday, Super Mario
RE
10/18TODAY'S LOGISTICS REPORT : Fred Smith's Growing FedEx Challenge; Seeking Rail Vo..
DJ
10/18JOHNSON & JOHNSON : Genmab, Janssen Get CHMP Positive Option for Expanded Darzal..
DJ
10/18SNAKES AND LADDERS : SoftBank Vision Fund's climbing, sliding valuations
RE
10/18European Businesses Give Draft Deal Cautious Welcome -- WSJ
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart NEKTAR THERAPEUTICS
Duration : Period :
Nektar Therapeutics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEKTAR THERAPEUTICS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 33,18  $
Last Close Price 17,20  $
Spread / Highest target 487%
Spread / Average Target 92,9%
Spread / Lowest Target -6,98%
EPS Revisions
Managers
NameTitle
Howard W. Robin President, Chief Executive Officer & Director
Robert B. Chess Chairman
John Nicholson Chief Operating Officer & Senior Vice President
Gilbert M. Labrucherie Chief Financial Officer & Senior Vice President
Stephen K. Doberstein Chief Research & Development Officer
Sector and Competitors
1st jan.Capitalization (M$)
NEKTAR THERAPEUTICS-47.67%3 015
IQVIA HOLDINGS INC.22.98%28 040
LONZA GROUP31.76%25 360
CELLTRION, INC.--.--%19 821
SEATTLE GENETICS, INC.74.09%17 145
INCYTE CORPORATION23.46%16 902